NUCIEN PHARMA(SH:688189) Xin Lang Cai Jing·2025-10-31 17:54Core Insights - Nanjing Pharmaceutical focuses on antiviral and major disease treatment drug research and development, with strong technical capabilities in the prevention and treatment of infectious diseases like influenza [1] Financial Performance - For Q3 2025, Nanjing Pharmaceutical reported revenue of 83.15 million yuan, ranking 106th among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which reported 32.664 billion yuan [2] - The company's net profit was -75.78 million yuan, ranking 90th in the industry, far behind the top performers, Heng Rui Pharmaceutical at 5.76 billion yuan and Fosun Pharmaceutical at 3.056 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 22.57%, an increase from 11.61% in the same period last year, but still below the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 33.44%, a significant decline from 60.76% in the previous year and below the industry average of 57.17% [3] Executive Compensation - The chairman and general manager, Zhang Shixi, received a salary of 735,500 yuan in 2024, a decrease of 272,700 yuan from 1,008,200 yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 49.13% to 14,100, while the average number of circulating A-shares held per shareholder decreased by 32.95% to 19,400 [5] - New major shareholders include several funds from GF Fund Management, with notable holdings of 5.4741 million shares, 5.3492 million shares, 3.8594 million shares, and 1.5945 million shares [5]